

RENOUNCEABLE UNDERWRITTEN RIGHTS ISSUE – RESULTS OF RIGHTS ISSUE

*The Board of Directors ("**Board**") of OUE Lippo Healthcare Limited ("**Company**") refers to the announcements made by the Company on 18 September 2018, 20 September 2018 and 1 October 2018 ("**Announcements**") and the offer information statement lodged with the SGX-ST acting as agent on behalf of MAS on 1 October 2018 ("**Offer Information Statement**") in relation to, inter alia, the renounceable underwritten rights issue. Unless defined herein, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Offer Information Statement.*

1. SUBSCRIPTION RESULTS

The Company wishes to announce that at the close of the Rights Issue on 17 October 2018, valid acceptances and excess applications were received for 2,090,941,906 Rights Shares, representing approximately 94.1% of the total 2,221,564,603 Rights Shares available under the Rights Issue (based on the existing Shares held by Shareholders as at the Books Closure Date, fractional entitlements (if applicable) to be disregarded). This includes acceptances by the Undertaking Shareholders for an aggregate of 1,992,014,500 Rights Shares pursuant to the Irrevocable Undertakings.

Details of the valid acceptances and excess applications received are as follows:

	Number of Rights Shares	As a percentage of the total number of Rights Shares
Valid Acceptances	2,061,872,334	92.8%
Excess Applications	29,069,572	1.3%
Total	2,090,941,906	94.1%

A total of 159,692,269 Rights Shares, comprising Rights Shares that are not validly taken up and Rights Shares that are not otherwise allotted for whatever reason in accordance with the terms and conditions contained in the Offer Information Statement, the ARE, the PAL and (if applicable) the Constitution of the Company, will be used to satisfy the applications for 29,069,572 excess Rights Shares. In the allotment of excess Rights Shares, preference will be given to the rounding of odd lots, and the Directors and the Substantial Shareholders who have control or influence over the Company in connection with the day-to-day affairs of the Company or the terms of the Rights Issue, or have representation (direct or through a nominee) on the Board will rank last in priority for the rounding of odd lots and allotment of excess Rights Shares.

The balance 130,622,697 Rights Shares will be underwritten by Oversea-Chinese Banking Corporation Limited on the terms and subject to the conditions of the Management and Underwriting Agreement.

2. CREDITING OF RIGHTS SHARES INTO SECURITIES ACCOUNTS

Upon the crediting of the Rights Shares and excess Rights Shares, CDP will send to successful subscribers, by ordinary post and at their own risk, a notification letter showing the number of Rights Shares and (if applicable) excess Rights Shares credited to their respective Securities Accounts.

3. REFUND OF SUBSCRIPTION MONIES

When any acceptance for Rights Shares and/or excess application is invalid or unsuccessful, the amount paid on acceptance and/or application will be returned or refunded to such applicants without interest or any share of revenue or other benefit arising therefrom within fourteen (14) days after the Closing Date as follows:

- (a) where the acceptance and/or application had been made through CDP, by means of a crossed cheque in Singapore currency drawn on a bank in Singapore and sent by ordinary post at their own risk within three (3) Market Days after the commencement of trading of the Rights Shares to their mailing address as maintained in the records of CDP or in such other manner as they may have agreed with CDP for the payment of any cash distributions;
- (b) where the acceptance and/or application had been made through the Share Registrar, by means of a crossed cheque in Singapore currency drawn on a bank in Singapore and sent by ordinary post at their own risk to their mailing address in Singapore as maintained with the Share Registrar, within 14 days after the Closing Date; and
- (c) where the acceptance and/or application had been made through Electronic Applications through an ATM of a Participating Bank, by crediting their bank accounts with the relevant Participating Banks at their own risk within three (3) Market Days after the commencement of trading of the Rights Shares, the receipt by such bank being a good discharge by the Company and CDP of their obligations.

4. DISTRIBUTION OF NET SALE PROCEEDS OF “NIL-PAID” RIGHTS TO FOREIGN SHAREHOLDERS

Of the total 2,684,622 “nil-paid” Rights which would otherwise have been provisionally allotted to Foreign Shareholders, a total of 2,684,600 “nil-paid” Rights have been sold on the SGX-ST. The net proceeds from all such sales, after deduction of all expenses therefrom, will be pooled and thereafter distributed to Foreign Shareholders in proportion to their respective shareholdings or, as the case may be, the number of Shares entered against their names in the Depository Register as at the Books Closure Date and sent to them at their own risk by ordinary post, provided that where the amount of net proceeds to be distributed to any single Foreign Shareholder or persons acting to the account or benefit of any such person is less than S\$10.00, the Company shall be entitled to retain or deal with such net proceeds as the Directors may, in their absolute discretion, deem fit in the interests of the Company and no Foreign Shareholder or persons acting to the account or benefit of any such person shall have any claim whatsoever against the Company, the Directors, the Manager and Underwriter, CDP, the Sponsor, the Share Registrar and/or their respective officers in connection therewith.

5. ALLOTMENT AND LISTING OF RIGHTS SHARES

The Rights Shares are expected to be allotted and issued on 23 October 2018 and listed and quoted on the Catalist of the SGX-ST with effect from 9.00 a.m. on or around 25 October 2018. The Company will release an announcement via SGXNET in due course in respect of the aforementioned.

Upon the listing and quotation of the Rights Shares on the Catalist of the SGX-ST, the Rights Shares will be traded on the Catalist of the SGX-ST under the book-entry (scripless) settlement system. All dealings in and transactions (including transfers) in relation to the Rights Shares effected through the SGX-ST and/or CDP shall be made in accordance with CDP's "Terms and Conditions for Operation of Securities Accounts with The Central Depository (Pte) Limited", as the same may be amended from time to time, copies of which are available from CDP.

For the purposes of trading on the Catalist, each board lot of Shares will comprise 100 Shares. Shareholders who hold odd lots of Shares (that is, lots other than board lots of 100 Shares) and who wish to trade in odd lots on the SGX-ST are able to trade odd lots of Shares in board lots of one Share on the Unit Share Market.

The Rights Shares will, upon allotment and issue, rank *pari passu* in all respects with the then issued Shares, save for any dividends, rights, allotments or other distributions, the record date for which falls before the date of issue of the Rights Shares.

The Company wishes to take this opportunity to thank Shareholders for their support towards the successful completion of the Rights Issue.

By Order of the Board,
OUE Lippo Healthcare Limited

Dr. Wong Weng Hong
Chief Executive Officer and Executive Director

19 October 2018

This announcement has been prepared by OUE Lippo Healthcare Limited (formerly known as International Healthway Corporation Limited) (the "Company") and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"), for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).